Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Francesca FerraroWashington University School of Medicine, Saint Louis, MO, USA. ferrarof@wustl.edu.ORCID 0000-0003-0098-9819
David L WiestFox Chase Cancer Center, Philadelphia, PA, USA. david.wiest@fccc.edu.ORCID 0000-0002-0792-3188
Stephen M SykesWashington University School of Medicine, Saint Louis, MO, USA. s.m.sykes@wustl.edu.ORCID 0000-0002-7330-0106
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
Regulation of hematopoiesis by ribosomal protein paralogsR37AI110985 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI DAVID L. WIEST · 2020 to 2026
$4.2M
Determining the Role and Targeting potential of Serine Metabolism in aggressive sub-types of Acute Myeloid LeukemiaR01CA273127 · NCI · WASHINGTON UNIVERSITY · PI Stephen Matthew Sykes · 2023 to 2026
$2.2M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Regulation of Hematopoiesis by Ribosomal Protein ParalogsR01AI110985 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI WIEST, DAVID L. · 2015 to 2019
$2.0M
Regulation of the mitotic DNA damage responseR35GM160196 · NIGMS · WASHINGTON UNIVERSITY · PI KRAIS, JOHN · 2025 to 2025
$1.9M
Targeting the Unfolded Protein Response in Leukemia Biology and Chemotherapy ResistanceR01CA227830 · NCI · WASHINGTON UNIVERSITY · PI SYKES, STEPHEN MATTHEW · 2019 to 2023
$1.9M
The Role of MYC Mutations in acute Myeloid LeukemiaK08CA252632 · NCI · WASHINGTON UNIVERSITY · PI FERRARO, FRANCESCA · 2021 to 2025
$1.1M
Purchase of a Q Exactive HF mass spectrometer system for metabolomicsS10OD023586 · OD · WISTAR INSTITUTE · PI SPEICHER, DAVID W. · 2017 to 2017
$600k
Orbitrap Exploris 480 Basic SystemS10OD030286 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SIDOLI, SIMONE · 2021 to 2021
$600k
American Cancer Society (American Cancer Society, Inc.) RSG-18-195-01-DDCNCI NIH HHS K08 CA252632NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA227830NCI NIH HHS R01 CA273127NCI NIH HHS R50 CA221838NIAID NIH HHS R01 AI110985NIAID NIH HHS R37 AI110985NIAID NIH HHS R56 AI110985NIGMS NIH HHS R35 GM160196NIH HHS S10 OD023586NIH HHS S10 OD030286U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA010815U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA171963U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA221838U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA227830U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA252632U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA273127U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA006927U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI110985U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM160196U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) OD023586U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) OD030286
6 · The paper itself
Abstract
Proper timing of DNA replication relies on sufficient nucleotide pools and replication machinery. The upstream regulatory programs that support the biomass production needed for DNA replication, particularly in the accelerated growth setting of cancer, remain incompletely defined. Here we show that the transcription factor ATF4 coordinates amino acid and nucleotide metabolism with selective protein synthesis to ensure proper DNA replication initiation and timing in acute leukemia. Specifically, ATF4 promotes the expression of enzymes that biosynthesize amino acids required for nucleotide production and drive the transcription of tRNA charging enzymes that sustain translation of a subset of proteins involved in replication origin firing. Consequently, ATF4 inhibition limits nucleotide biosynthesis and replication machinery, thereby disrupting DNA replication timing and leading to leukemia cell differentiation and death. Our findings indicate that ATF4 coordinates metabolic and translational programs to maintain DNA replication fidelity and the differentiation blockade in leukemia cells.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cells. · full record | OpenQuestion